@article{TGC1715,
author = {Ayham Ghinagow and Kirubakaran Malapan and Andrea Ooi Se and Anirudh Vij and Po-Chih Chang and Xiao-Yan Chen and Chih-Kun Huang},
title = {Mid-term results after single incision transumbilical laparoscopic sleeve gastrectomy},
journal = {Translational Gastrointestinal Cancer},
volume = {2},
number = {2},
year = {2013},
keywords = {},
abstract = {Background: laparoscopic sleeve gastrectomy (LSG) is gaining large popularity as a stand-alone bariatric procedure. Single incision laparoscopic surgery (SILS) was successfully used in bariatric surgery. In 2010, we published our preliminary results of single-incision transumbilical (SITU) laparoscopic bariatric surgery including 6 cases of SITU-LSG and the short term results were perfectly acceptable. In this study, we evaluate the short- and mid-term results of (SITU-LSG) including safety feasibility, efficacy, complications and cosmetic results.
Methods: Between November 2008 and November 2012, 51 morbidly obese patients underwent SITULSG. Data was prospectively collected and retrospectively analyzed.
Results: The mean age was 31 years (range, 18-50 years), and the mean preoperative body mass index (BMI) was 36.3 kg/m2 (range, 32.16-45.67 kg/m2). Patients were 13 males and 38 females. The procedure was successfully performed in all patients without inserting additional trocars or conversion to conventional 5 ports or open surgery. The mean operative time was 72 minutes (range, 30-170 minutes). No intraoperative complications occurred. The mean hospital stay was 2 days (range, 1-5 days). No mortality, leak, stricture, wound infection and incisional hernia occurred during 2 years of follow up. The excess weight loss (EWL%) was 73.8% (range, 48.43-102.95%) and 76.1% (range, 43.35-103.16%) at 1 year and 2 years after surgery. Most co-morbidities disappeared 2 years after surgery and patients were satisfied with the cosmetic results.
Conclusions: SITU-LSG is a feasible, safe bariatric procedure with acceptable cosmetic results and effective short to mid-term weight loss and resolution of comorbidities.},
url = {https://tgc.amegroups.com/article/view/1715}
}